Academic Journal
Προβολή σε EDS
Συνδεδεμένο Πλήρες Κείμενο

Nanomotor-Assisted Intravesical Chemotherapy for Bladder Tumor Reduction and Suppression of Early Tumor Regrowth.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Nanomotor-Assisted Intravesical Chemotherapy for Bladder Tumor Reduction and Suppression of Early Tumor Regrowth.
Συγγραφείς: Fichna K; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.; Doctorate in Biotechnology, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Avda. Diagonal 643, 08028 Barcelona, Spain., Crespo-Cuadrado M; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain., Konuparamban A; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramón 182, 20014 Donostia/San Sebastián, Spain., Di Carlo V; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain., Esporrín-Ubieto D; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain., Macías-Tarrío I; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.; Doctorate in Biotechnology, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Avda. Diagonal 643, 08028 Barcelona, Spain.; Departament de Bioquímica i Fisiologia Facultat de Farmácia i CCAA, Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain., Jutglar Soler O; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain., Chen S; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain., Gómez-Martínez M; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramón 182, 20014 Donostia/San Sebastián, Spain., Bakenecker AC; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain., Vilaseca A; Department of Urology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain., Llop J; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramón 182, 20014 Donostia/San Sebastián, Spain., Sánchez S; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.; Catalan Institution for Research and Advanced Studies (ICREA), Passeig Lluís Companys 23, 08010 Barcelona, Spain.
Πηγή: Nano letters [Nano Lett] 2026 May 06; Vol. 26 (17), pp. 5618-5627. Date of Electronic Publication: 2026 Apr 23.
Τύπος έκδοσης: Journal Article; Research Support, Non-U.S. Gov't
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101088070 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-6992 (Electronic) Linking ISSN: 15306984 NLM ISO Abbreviation: Nano Lett Subsets: MEDLINE
Imprint Name(s): Original Publication: Washington, DC : American Chemical Society, c2001-
Ιατρικοί όροι (MeSH): Mitomycin*/administration & dosage , Mitomycin*/therapeutic use , Mitomycin*/pharmacology , Mitomycin*/chemistry , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology , Nanoparticles*/chemistry , Antibiotics, Antineoplastic*/administration & dosage, Silicon Dioxide/chemistry ; Antineoplastic Agents/administration & dosage ; Animals ; Administration, Intravesical ; Mice ; Cell Line, Tumor ; Humans ; Drug Delivery Systems ; Non-Muscle Invasive Bladder Neoplasms ; Female
Περίληψη: Nanoparticles are widely used in nanomedicine for controlled drug delivery and improved bioavailability. However, their effectiveness is often limited by passive diffusion, especially in confined, fluid-filled environments like the bladder, where rapid drug clearance and uneven distribution reduce therapeutic impact. These challenges contribute to high recurrence in bladder cancer despite intravesical chemotherapy. To address this limitation, we present urease-powered nanomotors (NM) based on mesoporous silica nanoparticles loaded with Mitomycin C (MMC), the standard chemotherapeutic for nonmuscleinvasive bladder cancer. These NM useurea present in urine to induce motion and drug dispersion. In vitro, NM showed 2.3-fold higher uptake in mouse bladder cancer cells than passive nanoparticles and achieved the efficacy of free MMC (577.5 μg/mL) at a 20-fold lower dose (30 μg/mL). In vivo, a single intravesical dose reduced tumor volumes by 83% and prevented early tumor regrowth, demonstrating the potential of NM-based delivery for bladder cancer therapy.
References: Nano Lett. 2015 Dec 9;15(12):8311-5. (PMID: 26587897)
ACS Nano. 2019 Oct 22;13(10):12171-12183. (PMID: 31580642)
Adv Drug Deliv Rev. 2002 Sep 13;54(5):631-51. (PMID: 12204596)
ACS Nano. 2016 Oct 25;10(10):9111-9122. (PMID: 27666121)
ACS Appl Mater Interfaces. 2024 Sep 11;16(36):47192-47205. (PMID: 39262054)
Exp Eye Res. 2020 Aug;197:108124. (PMID: 32598971)
Adv Sci (Weinh). 2023 Mar;10(7):e2204643. (PMID: 36638276)
ACS Nano. 2023 Apr 25;17(8):7180-7193. (PMID: 37058432)
Signal Transduct Target Ther. 2018 Mar 16;3:7. (PMID: 29560283)
Angew Chem Int Ed Engl. 2015 Jan 26;54(5):1414-44. (PMID: 25504117)
Nat Nanotechnol. 2025 Aug;20(8):990-1000. (PMID: 40750672)
Eur Urol Focus. 2024 Jan;10(1):189-196. (PMID: 37442722)
Analyst. 2012 Feb 7;137(3):595-600. (PMID: 22179722)
Langmuir. 2012 Jul 31;28(30):10997-1006. (PMID: 22731393)
ACS Nano. 2025 Mar 11;19(9):8411-8432. (PMID: 39996616)
BJU Int. 2014 Nov;114(5):719-26. (PMID: 24325202)
Nat Biotechnol. 2015 Sep;33(9):941-51. (PMID: 26348965)
Nat Commun. 2024 Oct 29;15(1):9315. (PMID: 39472587)
ACS Appl Bio Mater. 2022 Dec 19;5(12):5554-5566. (PMID: 36399694)
Int J Pharm. 2009 Apr 17;371(1-2):170-6. (PMID: 19135514)
Pharm Res. 2008 Jul;25(7):1500-10. (PMID: 18369709)
Eur Urol. 2014 Aug;66(2):253-62. (PMID: 24472711)
Nano Lett. 2015 Oct 14;15(10):7077-85. (PMID: 26383602)
Signal Transduct Target Ther. 2023 Nov 3;8(1):418. (PMID: 37919282)
ACS Nano. 2018 Aug 28;12(8):8423-8435. (PMID: 30016073)
Eur Urol. 2013 Oct;64(4):639-53. (PMID: 23827737)
Phys Rev Lett. 2020 Mar 13;124(10):108001. (PMID: 32216443)
Pharmaceutics. 2021 Oct 25;13(11):. (PMID: 34834192)
ACS Nano. 2024 Jul 2;18(26):16701-16714. (PMID: 38885185)
Eur Urol. 2013 Sep;64(3):421-30. (PMID: 23830475)
Pharmaceutics. 2022 Jul 17;14(7):. (PMID: 35890378)
Nat Commun. 2024 Nov 15;15(1):9934. (PMID: 39548120)
Acta Pharm Sin B. 2021 Sep;11(9):2924-2936. (PMID: 34589405)
J Biol Chem. 1984 Jan 25;259(2):959-66. (PMID: 6319393)
Pharmaceutics. 2023 Dec 03;15(12):. (PMID: 38140065)
Angew Chem Int Ed Engl. 2007;46(40):7548-58. (PMID: 17854012)
Mol Pharmacol. 1986 Jun;29(6):622-8. (PMID: 3086708)
Nat Nanotechnol. 2020 Oct;15(10):819-829. (PMID: 32895522)
Chem Sci. 2022 Jul 21;13(32):9128-9146. (PMID: 36093007)
ACS Nanosci Au. 2022 Nov 25;3(1):94-102. (PMID: 37101464)
J Mater Chem B. 2024 Mar 13;12(11):2711-2719. (PMID: 38239179)
J Urol. 2004 Jun;171(6 Pt 1):2186-90, quiz 2435. (PMID: 15126782)
ACS Nano. 2019 Jan 22;13(1):429-439. (PMID: 30588798)
Proc Natl Acad Sci U S A. 1963 Aug;50:355-62. (PMID: 14060656)
J Control Release. 2010 Dec 1;148(2):147-59. (PMID: 20831887)
Nat Nanotechnol. 2024 Apr;19(4):554-564. (PMID: 38225356)
Pharmaceutics. 2021 Aug 31;13(9):. (PMID: 34575455)
Acc Chem Res. 2018 Nov 20;51(11):2662-2671. (PMID: 30346732)
J Nanobiotechnology. 2025 May 17;23(1):355. (PMID: 40380217)
Phys Rev Lett. 2007 Jul 27;99(4):048102. (PMID: 17678409)
J Am Chem Soc. 2018 Jun 27;140(25):7896-7903. (PMID: 29786426)
Nano Lett. 2015 Oct 14;15(10):7043-50. (PMID: 26437378)
ACS Nano. 2017 Jun 27;11(6):5367-5374. (PMID: 28467853)
Nanoscale. 2024 Feb 8;16(6):2904-2912. (PMID: 38054755)
Sci Robot. 2021 Mar 17;6(52):. (PMID: 34043548)
Ther Deliv. 2018 Mar 1;9(4):303-316. (PMID: 29540126)
Small. 2024 Mar;20(11):e2309387. (PMID: 38200672)
Contributed Indexing: Keywords: Bladder Cancer; Drug Delivery; Intravesical Chemotherapy; Mitomycin C; Nanomotors; Nanoparticles
Substance Nomenclature: 50SG953SK6 (Mitomycin)
7631-86-9 (Silicon Dioxide)
0 (Antibiotics, Antineoplastic)
0 (Antineoplastic Agents)
Entry Date(s): Date Created: 20260423 Date Completed: 20260715 Latest Revision: 20260912
Update Code: 20260913
PubMed Central ID: PMC13154347
DOI: 10.1021/acs.nanolett.5c05411
PMID: 42024786
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1530-6992
DOI:10.1021/acs.nanolett.5c05411